TAK-341-2001
Recruitment Complete
A Study of TAK-341 in Treatment of Multiple System Atrophy
About this clinical trial
The main aim is to see how TAK-341 works after 52 weeks in participants with multiple system atrophy as measured by the Unified Multiple System Atrophy Rating Scale Part I (UMSARS). The study will enroll approximately 138 patients. Participants will receive a total of 13 intravenous infusions every 4 weeks approximately, these may be either of TAK-341 or placebo, after each infusion some blood samplings will be taken and other assessments completed. This trial will be conducted in North America, Europe and Asia.
DE
US
ES
7+
Interventional Phase 2 clinical trial.
At a glance
What medical conditions were being studied?
Multiple System Atrophy
What was the clinical trial testing?
Placebo, TAK-341
How many participants were enrolled?
159
Were placebos part of the clinical trial?
Yes
When was the clinical trial conducted?
Nov 2022 - Jul 2025
How long was participation in the clinical trial?
Approximately 67 weeks including a follow-up visit.
Key requirements
Sexes
All
Age
40+ years
Healthy volunteers?
No
Entry criteria
Both men and women can take part.
Must be at least 40 years old.
Must have a diagnosis of possible or probable multiple system atrophy (MSA).
Must have an UMSARS Part I score of ≤21 (excluding Item #11, sexual function).
Additional entry criteria will be discussed with the study doctor.